Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells

Oncotarget

Volumn 7, Issue 17, 2016, Pages 23772-23784

  Aguirre Alvarado, Charmina ^a   Segura Cabrera, Aldo ^b   Velázquez Quesada, Inés ^c   Hernández Esquivel, Miguel A ^c   García Pérez, Carlos A ^c   Guerrero Rodríguez, Sandra L ^a   Ruiz Moreno, Angel J ^a   Rodríguez Moreno, Andrea ^a   Pérez Tapia, Sonia M ^c   Velasco Velázquez, Marco A ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO DE ECOLOGÍA   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Breast cancer; Cancer stem cells; CD44; Epithelial mesenchymal transition; Etoposide

Indexed keywords

BAFETINIB; BROMOCRIPTINE; CD24 ANTIGEN; CISPLATIN; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ELLIPTICINE; ETOPOSIDE; HERMES ANTIGEN; IRINOTECAN; MITOXANTRONE; NILOTINIB; SMOOTH MUSCLE ACTIN; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; CD44 PROTEIN, HUMAN; HYALURONIC ACID; HYALURONIC ACID BINDING PROTEIN; TUMOR MARKER;

ARTICLE; BINDING COMPETITION; BREAST CANCER CELL LINE; CANCER STEM CELL; CELL ADHESION; CELL ASSAY; CELL BINDING; CELL FUNCTION; CELL MIGRATION; CELL STRUCTURE; CELL VIABILITY; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; COMPLEX FORMATION; CONSENSUS DOCKING; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; HYALURONAN BINDING DOMAIN; INFORMATION PROCESSING; LIGAND BINDING; MAMMOSPHERE FORMATION; MDA MB 231 CELL LINE; MIGRATION INHIBITION; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PHENOTYPE; PROTEIN DOMAIN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; STRUCTURE BASED VIRTUAL SCREENING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; DRUG REPOSITIONING; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CD24 ANTIGEN; CELL PROLIFERATION; DRUG REPOSITIONING; EPITHELIAL-MESENCHYMAL TRANSITION; ETOPOSIDE; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYALURONAN RECEPTORS; HYALURONIC ACID; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84966559020     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8180     Document Type: Article

References (68)

1. Forman D, Ferlay J. (2014). The global and regional burden of cancer. In: Stewart BW, Wild CP, eds. World Cancer Report 2014. (Lyon, France: "International Agency for Research on Cancer"), pp. 64-185.
2. Group EBCTC. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687-1717.
3. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003; 4:33-45.
4. Corte MD, Gonzalez LO, Junquera S, Bongera M, Allende MT, Vizoso FJ. Analysis of the expression of hyaluronan in intraductal and invasive carcinomas of the breast. J Cancer Res Clin Oncol. 2010; 136:745-750.
5. Auvinen P, Tammi R, Kosma VM, Sironen R, Soini Y, Mannermaa A, Tumelius R, Uljas E, Tammi M. Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer. 2013; 132:531-539.
6. Collina F, Di Bonito M, Li Bergolis V, De Laurentiis M, Vitagliano C, Cerrone M, Nuzzo F, Cantile M, Botti G. Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer. Biomed Res Int. 2015; 2015:158682.
7. Masarwah A, Tammi M, Sudah M, Sutela A, Oikari S, Kosma VM, Tammi R, Vanninen R, Auvinen P. The reciprocal association between mammographic breast density, hyaluronan synthesis and patient outcome. Breast Cancer Res Treat. 2015; 153:625-634.
8. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, Cheng C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011; 121:1064-1074.
9. Preca BT, Bajdak K, Mock K, Sundararajan V, Pfannstiel J, Maurer J, Wellner U, Hopt UT, Brummer T, Brabletz S, Brabletz T, Stemmler MP. A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells. Int J Cancer. 2015; 137:2566-2577.
10. Zoltan-Jones A, Huang L, Ghatak S, Toole BP. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem. 2003; 278:45801-45810.
11. Chanmee T, Ontong P, Mochizuki N, Kongtawelert P, Konno K, Itano N. Excessive hyaluronan production promotes acquisition of cancer stem cell signatures through the coordinated regulation of Twist and the transforming growth factor beta (TGF-beta)-Snail signaling axis. J Biol Chem. 2014; 289:26038-26056.
12. Koyama H, Hibi T, Isogai Z, Yoneda M, Fujimori M, Amano J, Kawakubo M, Kannagi R, Kimata K, Taniguchi S, Itano N. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol. 2007; 170:1086-1099.
13. Hill A, McFarlane S, Mulligan K, Gillespie H, Draffin JE, Trimble A, Ouhtit A, Johnston PG, Harkin DP, McCormick D, Waugh DJ. Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells. Oncogene. 2006; 25:6079-6091.
14. Cieply B, Koontz C, Frisch SM. CD44S-hyaluronan interactions protect cells resulting from EMT against anoikis. Matrix Biol. 2015; 48:55-65.
15. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011; 9:997-1007.
16. Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, Zhou A, Eyob H, Balakrishnan S, Wang CY, Yaswen P, Goga A, Werb Z. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 2015; 526:131-135.
17. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704-715.
18. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PloS one. 2008; 3:e2888.
19. Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao X, Feng J, Zhang Y, Gao H, Liu DX, Lu J, Huang B. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res. 2012; 72:4597-4608.
20. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zurrer-Hardi U, Bell G, Tam WL, Mani SA, van Oudenaarden A, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell. 2012; 148:1015-1028.
21. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100: 3983-3988.
22. Chanmee T, Ontong P, Kimata K, Itano N. Key Roles of Hyaluronan and Its CD44 Receptor in the Stemness and Survival of Cancer Stem Cells. Front Oncol. 2015; 5:180.
23. Gao Y, Ruan B, Liu W, Wang J, Yang X, Zhang Z, Li X, Duan J, Zhang F, Ding R, Tao K, Dou K. Knockdown of CD44 inhibits the invasion and metastasis of hepatocellular carcinoma both in vitro and in vivo by reversing epithelial-mesenchymal transition. Oncotarget. 2015; 6:7828-7837. doi: 10.18632/oncotarget.3488.
24. Shigeishi H, Biddle A, Gammon L, Emich H, Rodini CO, Gemenetzidis E, Fazil B, Sugiyama M, Kamata N, Mackenzie IC. Maintenance of stem cell self-renewal in head and neck cancers requires actions of GSK3beta influenced by CD44 and RHAMM. Stem Cells. 2013; 31:2073-2083.
25. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008; 283:17635-17651.
26. Chen L, Bourguignon LY. Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Mol Cancer. 2014; 13:52.
27. Li L, Qi L, Liang Z, Song W, Liu Y, Wang Y, Sun B, Zhang B, Cao W. Transforming growth factor-beta1 induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cells. Int J Mol Med. 2015; 36:113-122.
28. Hiraga T, Ito S, Nakamura H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 2013; 73:4112-4122.
29. Louderbough JM, Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res. 2011; 9:1573-1586.
30. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10:515-527.
31. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K, Grabau D, Ferno M, Borg A, Hegardt C. The CD44+/CD24-phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008; 10:R53.
32. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A. 2010; 107:15449-15454.
33. Murohashi M, Hinohara K, Kuroda M, Isagawa T, Tsuji S, Kobayashi S, Umezawa K, Tojo A, Aburatani H, Gotoh N. Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells. Br J Cancer. 2010; 102:206-212.
34. Duan Q, Flynn C, Niepel M, Hafner M, Muhlich JL, Fernandez NF, Rouillard AD, Tan CM, Chen EY, Golub TR, Sorger PK, Subramanian A, Ma'ayan A. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res. 2014; 42:W449-460.
35. Bajorath J, Greenfield B, Munro SB, Day AJ, Aruffo A. Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J Biol Chem. 1998; 273:338-343.
36. Teriete P, Banerji S, Noble M, Blundell CD, Wright AJ, Pickford AR, Lowe E, Mahoney DJ, Tammi MI, Kahmann JD, Campbell ID, Day AJ, Jackson DG. Structure of the regulatory hyaluronan binding domain in the inflammatory leukocyte homing receptor CD44. Mol Cell. 2004; 13:483-496.
37. Herrera-Gayol A, Jothy S. Effects of hyaluronan on the invasive properties of human breast cancer cells in vitro. Int J Exp Pathol. 2001; 82:193-200.
38. Chang G, Wang J, Zhang H, Zhang Y, Wang C, Xu H, Zhang H, Lin Y, Ma L, Li Q, Pang T. CD44 targets Na(+)/H(+) exchanger 1 to mediate MDA-MB-231 cells' metastasis via the regulation of ERK1/2. Br J Cancer. 2014; 110:916-927.
39. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138:645-659.
40. Wu CC, Li TK, Farh L, Lin LY, Lin TS, Yu YJ, Yen TJ, Chiang CW, Chan NL. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science. 2011; 333:459-462.
41. Soubeyrand S, Pope L, Hache RJ. Topoisomerase IIalpha-dependent induction of a persistent DNA damage response in response to transient etoposide exposure. Mol Oncol. 2010; 4:38-51.
42. Li Z, Sun B, Clewell RA, Adeleye Y, Andersen ME, Zhang Q. Dose-response modeling of etoposide-induced DNA damage response. Toxicol Sci. 2014; 137:371-384.
43. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene. 1990; 5:893-899.
44. Gartel AL, Feliciano C, Tyner AL. A new method for determining the status of p53 in tumor cell lines of different origin. Oncol Res. 2003; 13:405-408.
45. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 1999; 18:477-485.
46. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001; 3:973-982.
47. Zhou B, Damrauer JS, Bailey ST, Hadzic T, Jeong Y, Clark K, Fan C, Murphy L, Lee CY, Troester MA, Miller CR, Jin J, Darr D, et al. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest. 2014; 124:553-563.
48. Kumar V, Krishna S, Siddiqi MI. Virtual screening strategies: recent advances in the identification and design of anti-cancer agents. Methods. 2015; 71:64-70.
49. Shi XN, Li H, Yao H, Liu X, Li L, Leung KS, Kung HF, Lu D, Wong MH, Lin MC. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug. PloS one. 2015; 10:e0132072.
50. Martin M, Lluch A, Casado A, Santabarbara P, Adrover E, Valverde JJ, Lopez-Martin JA, Rodriguez-Lescure A, Azagra P, Garcia-Conde J, et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol. 1994; 12:986-991.
51. Calvert AH, Lind MJ, Millward MM, Cantwell BM, Gumbrell L, Proctor M, Simmons D, Chapman F, Robinson A, Charlton C, et al. Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results. Cancer Treat Rev. 1993; 19 Suppl C: 27-33.
52. Yuan P, Di L, Zhang X, Yan M, Wan D, Li L, Zhang Y, Cai J, Dai H, Zhu Q, Hong R, Xu B. Efficacy of oral Etoposide in pretreated metastatic breast cancer: a multicenter phase 2 study. Medicine (Baltimore). 2015; 94:e774.
53. Wu PF, Lin CH, Kuo CH, Chen WW, Yeh DC, Liao HW, Huang SM, Cheng AL, Lu YS. A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis. BMC Cancer. 2015; 15:299.
54. Srinivas C, Ramaiah MJ, Lavanya A, Yerramsetty S, Kavi Kishor PB, Basha SA, Kamal A, Bhadra U, Bhadra MP. Novel Etoposide Analogue Modulates Expression of Angiogenesis Associated microRNAs and Regulates Cell Proliferation by Targeting STAT3 in Breast Cancer. PloS one. 2015; 10:e0142006.
55. Volkamer A, Kuhn D, Grombacher T, Rippmann F, Rarey M. Combining global and local measures for structure-based druggability predictions. J Chem Inf Model. 2012; 52:360-372.
56. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model. 2012; 52:1757-1768.
57. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2009; 31:455-461.
58. Neudert G, Klebe G. DSX: a knowledge-based scoring function for the assessment of protein-ligand complexes. J Chem Inf Model. 2011; 51:2731-2745.
59. Case DA, Cheatham TE, 3rd, Darden T, Gohlke H, Luo R, Merz KM, Jr., Onufriev A, Simmerling C, Wang B, Woods RJ. The Amber biomolecular simulation programs. J Comput Chem. 2005; 26:1668-1688.
60. Zlenko DV. Diffusion factor calculation for TIP4P model of water [Article in Russian]. Biofizika. 2012; 57:197-204.
61. Salomon-Ferrer R, Case DA, Walker RC. An overview of the Amber biomolecular simulation package. WIREs Comput Mol Sci. 2013; 3:198-210.
62. Oertli B, Fan X, Wuthrich RP. Characterization of CD44-mediated hyaluronan binding by renal tubular epithelial cells. Nephrol Dial Transplant. 1998; 13:271-278.
63. Lesley J, Gal I, Mahoney DJ, Cordell MR, Rugg MS, Hyman R, Day AJ, Mikecz K. TSG-6 modulates the interaction between hyaluronan and cell surface CD44. J Biol Chem. 2004; 279:25745-25754.
64. Velasco-Velazquez MA, Agramonte-Hevia J, Barrera D, Jimenez-Orozco A, Garcia-Mondragon MJ, Mendoza-Patino N, Landa A, Mandoki J. 4-Hydroxycoumarin disorganizes the actin cytoskeleton in B16-F10 melanoma cells but not in B82 fibroblasts, decreasing their adhesion to extracellular matrix proteins and motility. Cancer Lett. 2003; 198: 179-186.
65. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991; 3:207-212.
66. Zimmermann M, Meyer N. Annexin V/7-AAD staining in keratinocytes. Methods Mol Biol. 2011; 740:57-63.
67. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R, Jr., Badve S, Nakshatri H. CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006; 8:R59.
68. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003; 17:1253-1270.